Zanidatamab + chemotherapy for first-line (1L) treatment of HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma (mGEA): New and updated data from a phase II trial Meeting Abstract
| Authors: | Elimova, E.; Ajani, J. A.; Burris, H. A.; Denlinger, C. S.; Iqbal, S.; Kang, Y. K.; Kim, J. H.; Lee, K. W.; Lin, B.; Mehta, R.; Oh, D. Y.; Rha, S. Y.; Seol, Y. M.; Xie, C.; Garfin, P.; Ku, G. Y. |
| Abstract Title: | Zanidatamab + chemotherapy for first-line (1L) treatment of HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma (mGEA): New and updated data from a phase II trial |
| Meeting Title: | ESMO Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sep 13-17 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | S887 |
| End Page: | S888 |
| Language: | English |
| ACCESSION: | WOS:001326612902045 |
| DOI: | 10.1016/j.annonc.2024.08.1489 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1423P -- Source: Wos |
